Krieger Janice L, Palmer-Wackerly Angela, Dailey Phokeng M, Krok-Schoen Jessica L, Schoenberg Nancy E, Paskett Electra D
College of Journalism and Communications, University of Florida, Gainesville, FL, USA.
STEM Translational Communication Research Program, College of Journalism and Communications, University of Florida, Gainesville, FL, 32611, USA.
J Cancer Educ. 2015 Dec;30(4):743-8. doi: 10.1007/s13187-015-0789-0.
Comprehension of randomization is a vital, but understudied, component of informed consent to participate in cancer randomized clinical trials (RCTs). This study examines patient comprehension of the randomization process as well as sources of ongoing uncertainty that may inhibit a patient's ability to provide informed consent to participate in RCTs. Cancer patients living in rural Appalachia who were offered an opportunity to participate in a cancer treatment RCT completed in-depth interviews and a brief survey. No systematic differences in randomization comprehension between patients who consented and those who declined participation in a cancer RCT were detected. Comprehension is conceptually distinct from uncertainty, with patients who had both high and low comprehension experiencing randomization-related uncertainty. Uncertainty about randomization was found to have cognitive and affective dimensions. Not all patients enrolling in RCTs have a sufficient understanding of the randomization process to provide informed consent. Healthcare providers need to be aware of the different types of randomization-related uncertainty. Efforts to improve informed consent to participate in RCTs should focus on having patients teach back their understanding of randomization. This practice could yield valuable information about the patient's cognitive and affective understanding of randomization as well as opportunities to correct misperceptions. Education about RCTs should reflect patient expectations of individualized care by explaining how all treatments being compared are appropriate to the specifics of a patient's disease.
对随机分组的理解是参与癌症随机临床试验(RCT)知情同意的一个至关重要但研究不足的组成部分。本研究考察了患者对随机分组过程的理解以及可能阻碍患者提供参与RCT知情同意能力的持续不确定性来源。居住在阿巴拉契亚农村地区、有机会参与癌症治疗RCT的癌症患者完成了深入访谈和简短调查。未发现同意参与和拒绝参与癌症RCT的患者在随机分组理解上存在系统差异。理解在概念上与不确定性不同,理解程度高和低的患者都经历了与随机分组相关的不确定性。发现随机分组的不确定性具有认知和情感维度。并非所有参与RCT的患者都对随机分组过程有足够的理解以提供知情同意。医疗保健提供者需要意识到与随机分组相关的不同类型的不确定性。提高参与RCT知情同意的努力应侧重于让患者反馈他们对随机分组的理解。这种做法可以产生有关患者对随机分组的认知和情感理解的有价值信息,以及纠正误解的机会。关于RCT的教育应通过解释所有被比较的治疗方法如何适合患者疾病的具体情况来反映患者对个性化护理的期望。